Press Releases

Apr 17, 2018

LivaNova Receives CE Mark for VNS Therapy SenTiva Generator and Next-Generation Programming System for Treatment of Epilepsy

LONDON--(BUSINESS WIRE)--Apr. 17, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it received CE Mark for its Vagus Nerve Stimulation Therapy® (“VNS Therapy”) System comprised of the SenTiva® generator and next-generation Programming System for the treatment of patients with drug-resistant epilepsy (“DRE”). The Company received FDA approval for the full VNS Therapy Syste... Read More
  
Apr 05, 2018

LivaNova to Host Conference Call for First Quarter 2018 Results

LONDON--(BUSINESS WIRE)--Apr. 5, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, will host a conference call to discuss its first quarter 2018 results on Wednesday, May 2, 2018 at 8 a.m. CST (2 p.m. GMT). The Company will release its first quarter 2018 results earlier that day, before the open of the U.S. financial markets. A live webcast of the conference call will be a... Read More
  
Apr 04, 2018

LivaNova Completes Acquisition of TandemLife

LONDON--(BUSINESS WIRE)--Apr. 4, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it closed its acquisition of TandemLife. Previously, on Feb. 14, LivaNova announced its intent to acquire TandemLife, a privately held company focused on advanced cardiopulmonary temporary support solutions. “The acquisition of TandemLife allows us to complement our portfolio with a ... Read More
  
Mar 29, 2018

LivaNova Bicarbon Aortic Valves Receive CE Mark for Expanded Use Labeling with Lower-Dose Blood Thinners in Low-Risk Patients

LONDON--(BUSINESS WIRE)--Mar. 29, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, has received CE Mark approval for its Bicarbon® aortic valves for use with low-dose anticoagulant therapy. The expanded CE labeling means that a lower international normalized ratio (INR), the standardized index used to measure blood coagulability, can be targeted following Bicarbon aortic valve implantati... Read More
  
Mar 28, 2018

LivaNova Commences Clinical Study to Evaluate Treatment Outcomes for Novel Microburst VNS Therapy System

LONDON--(BUSINESS WIRE)--Mar. 28, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced the launch and enrollment of the first patient in a clinical study to examine the use of LivaNova’s new Microburst Vagus Nerve Stimulation Therapy® (“VNS Therapy”) System. This feasibility study will determine the initial safety and effectiveness of delivering VNS Therapy using high frequen... Read More
  
Mar 22, 2018

LivaNova Announces Enrollment for PERFECT Perceval Valve Clinical Trial in China

Pre-market trial to demonstrate safety and effectiveness of Perceval sutureless aortic heart valve LONDON--(BUSINESS WIRE)--Mar. 22, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, has announced the first patient enrollment in the Perceval® Valve Clinical study for Chinese Registration (“PERFECT”) Trial. The study is a pre-market, prospective, single-arm trial. The PERFECT trial is ... Read More
  
Mar 20, 2018

LivaNova to Present at the Needham & Company Healthcare Conference

LONDON--(BUSINESS WIRE)--Mar. 20, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced Thad Huston, Chief Financial Officer of LivaNova, will present at the Needham & Company Healthcare Conference in New York on Tuesday, March 27 at 8:30 a.m. Eastern Daylight Time. The discussion will be available to all interested parties through a live audiocast accessible via t... Read More
  
Mar 08, 2018

LivaNova Enters into Definitive Agreement to Divest Its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation

LONDON--(BUSINESS WIRE)--Mar. 8, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) today announced that it has entered into a definitive Stock and Asset Purchase Agreement (“Purchase Agreement”) to divest its Cardiac Rhythm Management business franchise to MicroPort Scientific Corporation (“MicroPort”). LivaNova and MicroPort executed and delivered the Purchase Agreement, pursuant to the terms of a binding Letter of Intent, previously announced on November ... Read More
  
Feb 28, 2018

LivaNova Reports Fourth Quarter and Full-Year 2017 Results

LONDON--(BUSINESS WIRE)--Feb. 28, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2017. For the fourth quarter of 2017, worldwide sales from continuing operations were $278.4 million, an increase of 11.5 percent on a reported basis and an increase of 8.1 percent on a constant currency basis, a... Read More
  
Feb 15, 2018

LivaNova to Present at the Barclays and Cowen Conferences

LONDON--(BUSINESS WIRE)--Feb. 15, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced company executives will present at two upcoming healthcare conferences taking place on Tuesday, March 13. Chief Executive Officer Damien McDonald will participate in the Barclays Global Healthcare Conference 2018 in Miami at 9 a.m. Eastern Time. At 12 p.m. Eastern Time, Chief Financial Officer ... Read More
  
Feb 14, 2018

LivaNova to Acquire TandemLife

Company will add advanced cardiopulmonary temporary support solutions to its portfolio LONDON--(BUSINESS WIRE)--Feb. 14, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it has entered into an agreement to acquire TandemLife, a privately held company focused on advanced cardiopulmonary temporary support solutions (“TandemLife”). The Pittsburgh-based company offers fou... Read More
  
Feb 01, 2018

LivaNova Announces CE Mark for PureFlex Arterial Cannulae Line for Conventional Cardiac Surgery

Company celebrates new design that delivers improved flexibility, clarity and control LONDON--(BUSINESS WIRE)--Feb. 1, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it has achieved CE Mark for its new PureFlexTM line of adult arterial cannulae. Engineered to improve the critical link between the patient and extracorporeal circulation, PureFlex cannulae provide curv... Read More
  
Jan 24, 2018

LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2017 Results

LONDON--(BUSINESS WIRE)--Jan. 24, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, will host a conference call to discuss its fourth quarter and full-year 2017 results on Wednesday, Feb. 28, 2018 at 8 a.m. CST (2 p.m. GMT). The Company will release its fourth quarter and full-year 2017 results earlier that morning, before the open of the U.S. financial markets. A live web... Read More
  
Jan 11, 2018

LivaNova Initiates BELIEVE Aortic Heart Valve Study in the U.S. and Canada

Company is advancing clinical research with three aortic valve studies LONDON--(BUSINESS WIRE)--Jan. 11, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced that the first patient has been enrolled in the Behavior of Valve Leaflets and the Incidence of Reduced Mobility Post-Surgical Aortic Valve Implant Study (“BELIEVE”). This study is a post-market, prospective, interve... Read More
  
Jan 08, 2018

LivaNova Announces Matthew J. Dodds as Senior Vice President, Corporate Development

LONDON--(BUSINESS WIRE)--Jan. 8, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced Matthew J. Dodds has joined the Company as Senior Vice President, Corporate Development. In this role, Dodds is responsible for Business Development, Investor Relations and Corporate Communications. “Matt brings an outstanding perspective on the industry and macroeconomic trends that... Read More
  
Jan 04, 2018

LivaNova Commences Global RESTORE-LIFE Study for Treatment-Resistant Depression

First patient enrolled to assess the effectiveness and efficiency of VNS Therapy as adjunctive treatment LONDON--(BUSINESS WIRE)--Jan. 4, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced the launch and enrollment of the first patient in the Global Prospective, Multi-center, Observational Post-market Study to Assess Short-, Mid- and Long-term Effectiveness and E... Read More